NICE rebuffs Gilead’s Yescarta, second setback for an orphan therapy this month

One day after the European Commission approved CAR T therapy Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD), U.K.'s NICE published draft guidance recommending against the use of therapy. The guidance applies to adults with relapsed or refractory diffuse large B cell lymphoma (DLBCL) who have received two or more lines of

Read the full 587 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE